Asian Pacific journal of allergy and immunology最新文献_第4页

A unique profile of serum cytokines in type 1 autoimmune pancreatitis and chronic rhinosinusitis. 1 型自身免疫性胰腺炎和慢性鼻炎患者血清细胞因子的独特特征。

IF 5 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01 DOI: 10.12932/AP-311020-0990

Tomoe Yoshikawa, Kosuke Minaga, Akane Hara, Ikue Sekai, Yasuo Otsuka, Ryutaro Takada, Ken Kamata, Tomohiro Watanabe, Masatoshi Kudo

{"title":"A unique profile of serum cytokines in type 1 autoimmune pancreatitis and chronic rhinosinusitis.","authors":"Tomoe Yoshikawa, Kosuke Minaga, Akane Hara, Ikue Sekai, Yasuo Otsuka, Ryutaro Takada, Ken Kamata, Tomohiro Watanabe, Masatoshi Kudo","doi":"10.12932/AP-311020-0990","DOIUrl":"10.12932/AP-311020-0990","url":null,"abstract":"Background: Type 1 autoimmune pancreatitis (AIP) is a pancreatic manifestation of IgG4-related disease (IgG4-RD). Although AIP and IgG4-RD are characterized by multiple organ involvement including salivary glands, lung, and kidney, co-occurrence of chronic rhinosinusitis (CRS) and AIP/IgG4-RD has been poorly defined.Objective: We explored molecular mechanism accounting for the co-occurrence of CRS and AIP/IgG4-RD.Methods: Serum concentrations of IFN-α and IL-33 were measured by enzyme-linked immune-sorbent assay.Results: We encountered a patient with concurrent type 1 AIP/IgG4-RD and CRS. Induction of remission by prednisolone (PSL) for type 1 AIP/IgG4-RD led to a marked improvement of CRS. Serum cytokine analysis after PSL treatment revealed a marked reduction in serum concentrations of IFN-α and IL-33, both of which are candidate pathogenic cytokines for AIP/IgG4-RD.Conclusions: Given that IL-33 is shared as one of pathogenic cytokines by type 1 AIP/IgG4-RD and CRS, enhanced IL33 responses may cause concurrent type 1 AIP/IgG4-RD and CRS.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25411603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immediate allergic reaction to thiocolchicoside confirmed by skin testing and basophil activation test: A case report and literature review. 经皮肤测试和嗜碱性粒细胞活化测试证实的硫代胆碱苷即刻过敏反应：病例报告和文献综述。

IF 2.3 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01 DOI: 10.12932/AP-250320-0793

Nucera Eleonora, Inchingolo Riccardo, Ferraironi Manuela, Aruanno Arianna, Chini Raffaella, Rizzi Angela

引用次数: 0

Disease activity of patients with chronic urticaria receiving COVID-19 vaccines. 接种 COVID-19 疫苗的慢性荨麻疹患者的疾病活动情况。

IF 5 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01 DOI: 10.12932/AP-160322-1345

Papapit Tuchinda, Kanokvalai Kulthanan, Leena Chularojanamontri, Bawonpak Pongkittilar, Oraya Pochanapan, Chuda Rujitharanawong

{"title":"Disease activity of patients with chronic urticaria receiving COVID-19 vaccines.","authors":"Papapit Tuchinda, Kanokvalai Kulthanan, Leena Chularojanamontri, Bawonpak Pongkittilar, Oraya Pochanapan, Chuda Rujitharanawong","doi":"10.12932/AP-160322-1345","DOIUrl":"10.12932/AP-160322-1345","url":null,"abstract":"Background: Cutaneous adverse events after receiving a COVID-19 vaccine were identified. The disease activity of urticaria after a COVID-19 vaccine has never been explored in chronic urticaria patients.Objective: To evaluate disease activity of chronic urticaria after receiving a COVID-19 vaccine.Methods: A prospective cross-sectional study was conducted in chronic urticaria patients aged 18 or above who visited Siriraj Hospital between July and September 2021, and received the first and second dose of COVID-19 vaccine. The status prior to vaccination, including disease activity, disease control and disease severity was assessed by a urticaria activity score over seven days, urticaria control test, and modified medication score. The disease activity after vaccination was recorded.Results: A total of 130 patients with a mean age of 45.9 ± 14.7 were enrolled in this study. Adenoviral and inactivated vaccines were administered to 85 (65.4%) and 45 patients (34.6%), respectively. Exacerbation was reported in 20 cases (15.4%) after the first dose and 17 cases (13.1%) after the second dose. Nine patients (45%) reported exacerbation after both the first and second dose. The majority of patients only had wheal, while three patients reported wheal with angioedema. No anaphylaxis was reported. Factor predicting exacerbation was concurrent thyroid disease (aRR 2.78, p < 0.01).Conclusions: Approximately 15% of chronic urticaria patients reported exacerbation after receiving a COVID-19 vaccination. No serious events were observed. Chronic urticaria patients should be vaccinated against COVID-19 after a discussion of the risk of disease flare-up.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40667268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The relationship between the rs4986791 variant of the TLR4 gene and the severity of bronchial asthma in children. TLR4 基因 rs4986791 变异与儿童支气管哮喘严重程度的关系。

IF 2.3 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01 DOI: 10.12932/AP-100920-0954

Xiaoqing Chen, Kai Wang, Qin Yao, Lixin Peng, Lin Wei

{"title":"The relationship between the rs4986791 variant of the TLR4 gene and the severity of bronchial asthma in children.","authors":"Xiaoqing Chen, Kai Wang, Qin Yao, Lixin Peng, Lin Wei","doi":"10.12932/AP-100920-0954","DOIUrl":"10.12932/AP-100920-0954","url":null,"abstract":"Background: Toll-like receptor 4 (TLR4) is an important receptor for lipopolysaccharide and lipid A, components of gram-negative bacteria. At present, a variant in TLR4 has been shown to be associated with asthma, but it has not been reported whether variants in TLR4 are associated with bronchial asthma in children.Objective: The objective is to determine the relationship between the rs4986791 (+1196C/T) variants of TLR4 and bronchial asthma in Chinese children.Methods: DNA extracted from peripheral blood samples was amplified and the Bi-PASA technique was carried out to identify the genotypes in 600 patients.Results: The result showed no difference between the 1196 C/T variant of TLR4 and hemoglobin level, proportion of neutrophils and lymphocytes, leukocyte, basophil and eosinophil counts, log10IgE and hsCRP in the peripheral blood of bronchial asthmatic patients. However, the eosinophil ratio, FEV1% and FEV1/FVC level of asthma patients with the CT genotype was lower than those of patients with the CC genotype, which were 1.19 ± 0.10 and 1.67 ± 0.18 (P = 0.01), 81.25 ± 0.50 and 84.99 ± 0.65 (P < 0.0001), 81.72 ± 0.568 and 5.55 ± 0.78 (P < 0.0001), respectively. The incidence of bronchial asthma in patients with the CT genotype is higher than that in patients with the CC genotype. We analysed the influence of the two genotypes on the current medical history by multiple logistic regression, performing a comparative analysis between the two genotypes and bronchial asthma (P < 0.05). Patients with moderately persistent asthma with the CT genotype are more likely to develop severely persistent asthma compared to those with the CC genotype (P < 0.01).Conclusions: This comparative analysis between rs4986791 and bronchial asthma in children indicates that this variant is associated with bronchial asthma risk in Chinese children.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39172755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sensitization to cat and dog components and prediction of symptoms in cat-sensitized children. 对猫和狗成分的敏感性以及对猫敏感儿童症状的预测。

IF 5 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01 DOI: 10.12932/AP-070920-0953

Katarzyna Smejda, Joanna Jerzynska, Daniela Podlecka, Agnieszka Brzozowska

{"title":"Sensitization to cat and dog components and prediction of symptoms in cat-sensitized children.","authors":"Katarzyna Smejda, Joanna Jerzynska, Daniela Podlecka, Agnieszka Brzozowska","doi":"10.12932/AP-070920-0953","DOIUrl":"10.12932/AP-070920-0953","url":null,"abstract":"Background: Sensitization to cat and/or dog allergens during childhood represents a risk factor for the development of allergic diseases later in life.Objective: The study investigated the association of patterns of sensitization to cat and dog allergen components with clinical symptoms of allergy to these furry animals among cat-sensitized children.Methods: The children were evaluated for the presence of bronchial asthma, atopic dermatitis and allergic rhinitis. Their mothers completed a questionnaire on pet exposure at home. Levels of serum IgE cat epitopes Fel d (1, 2, 4), as well as dog components Can f (1, 2, 3, 5) were measured in all the studied children.Results: Respiratory symptoms following exposure to the cat allergen were most common in children with Fel d 2 epitope (p = 0.041). After contact with a dog, respiratory symptoms were most common in children with Can f 1 epitope (p = 0.042), atopic dermatitis in children with sensitization to both Can f 1 (p = 0.009) and Can f 2 (p = 0.002), whereas eye symptoms occurred mostly in children with Can f 3 (p = 0.039).Conclusions: Molecular diagnosis in patients with pet allergy may help clinicians to predict clinical symptoms and their severity.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38882879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum: Request to Include COA Number Beta-Expansin of Bermuda, Johnson, and Para grass pollens, is a major cross-reactive allergen for allergic rhinitis patients in subtropical climate. 更正：请求包含 COA 编号百慕大、约翰逊和帕拉草花粉的 Beta-Expansin 是亚热带气候过敏性鼻炎患者的主要交叉反应过敏原。

IF 5 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01

引用次数: 0

Host factors influencing variable symptoms of COVID-19. 影响 COVID-19 不同症状的宿主因素。

IF 2.3 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01 DOI: 10.12932/AP-091023-1708

Tirasask Pasharawipas

引用次数: 0

Successful treatment of neurocysticercosis with albendazole desensitization. 阿苯达唑脱敏疗法成功治疗了神经囊虫病。

IF 2.3 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01 DOI: 10.12932/AP-191020-0983

Anh P Nguyen, Wesley Hoffman, Bennett H Penn, David Pham, Suzanne S Teuber

引用次数: 0

Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria. 慢性自发性荨麻疹患者接受奥马珠单抗治疗后，抑郁评分发生了明显变化。

IF 5 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01 DOI: 10.12932/AP-180920-0965

Pelin Kuteyla Can, Piril Etikan, Ece Nur Degirmentepe, Emek Kocaturk

{"title":"Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.","authors":"Pelin Kuteyla Can, Piril Etikan, Ece Nur Degirmentepe, Emek Kocaturk","doi":"10.12932/AP-180920-0965","DOIUrl":"10.12932/AP-180920-0965","url":null,"abstract":"Background: Chronic spontaneous urticaria (CSU) is frequently associated with psychiatric comorbidities.Objective: We aimed to determine if depressive symptoms were present in CSU patients who received omalizumab and if depression scores got better with omalizumab treatment and whether the presence of depressive symptoms impaired treatment responses.Methods: CSU patients who received at least three injections of omalizumab were included in the study. Changes in Urticaria Activity Score (UAS), Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), Beck Depression Inventory (Beck-D) and Urticaria Control Test (UCT) scores were compared before and after treatment.Results: From 49 patients, 20 (40.8%) had depressive symptoms at baseline. After treatment, UAS7, CU-Q2oL, Beck-D scores decreased and UCT-scores increased significantly (p < 0.001, for all). UCT scores were lower at baseline and at 3rd month following treatment in patients with depressive symptoms compared to patients without (baseline median (interquartile range-IQR) 2.5 (1-5) vs 5 (2.5-6.5); p = 0.04 and 3rd month 12 (9-13) vs 14 (12-16); p = 0.006, respectively). Omalizumab non-responders had higher baseline Beck-D-scores [18.5 (15.2-22) vs 12 (6-22.5); p = 0.031]. The number of omalizumab non-responders were significantly higher among patients with depressive symptoms compared to patients without. (40% vs 13.8%; p = 0.048). Only 6 patients scored as having depressive symptoms after treatment; of these 6 patients only one was an omalizumab responder.Conclusions: Omalizumab not only provides symptom control for urticaria but also improves psychological conditions of the patients. Coexistent psychiatric comorbidities should be taken into account in CSU patients since these conditions might impair treatment response.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25411604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data. 药物疗法对抗组胺药难治性慢性自发性荨麻疹的疗效：真实生活数据。

IF 5 4区医学

Asian Pacific journal of allergy and immunology Pub Date : 2024-06-01 DOI: 10.12932/AP-270820-0948

Mehmet Unsel

{"title":"Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data.","authors":"Mehmet Unsel","doi":"10.12932/AP-270820-0948","DOIUrl":"10.12932/AP-270820-0948","url":null,"abstract":"Background: Omalizumab is a safe and effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU) but is insufficient in one-third of patients. For serious cases in which omalizumab is ineffective, cyclosporine or methotrexate may be preferred. Most drug trials in CSU have focused on omalizumab or cyclosporine monotherapy.Objective: This retrospective study evaluated responses to monotherapy or combined therapy and real-life data on the effectiveness and safety of omalizumab in antihistamine-refractory CSU.Methods: A total of 133 patients who received omalizumab due to antihistamine-refractory CSU were evaluated in terms of 7-day urticaria activity score, total IgE, anti-thyroid peroxidase, C-reactive protein, skin prick test with aeroallergens and disease duration. Partial or nonresponders to omalizumab monotherapy were given antihistamine, omalizumab, cyclosporine, and methotrexate as combined or monotherapy.Results: Ninety-eight (73.7%) of the 133 patients were female and the mean age was 40.7 ± 14.4 years; 70.6% of the patients received omalizumab monotherapy and the others received combined or non-omalizumab monotherapy. Omalizumab monotherapy was effective in 66.9% of the patients. Of those with complete response to omalizumab monotherapy, 65.4% had early recurrence after discontinuing treatment. Treatment response was significantly better in patients who had high total IgE (p = 0.001). Patients with longer disease duration had significantly higher likelihood of early recurrence (p = 0.035).Conclusions: Omalizumab monotherapy was as effective in real life as in placebo-controlled trials. Omalizumab was well tolerated by all patients. Treatment responses were comparable in patients treated with combined therapy and those who received monotherapy.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25411606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0